Formaggio, Nicolò; Rubin, Mark A.; Theurillat, Jean-Philippe (2021). Loss and revival of androgen receptor signaling in advanced prostate cancer. Oncogene, 40(7), pp. 1205-1216. Springer Nature 10.1038/s41388-020-01598-0
|
Text
41388_2020_Article_1598.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully implemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate into AR-negative disease. Unfortunately, this process is intimately linked with a poor prognosis. Here, we review the molecular mechanisms that enable cancer cells to switch from an AR-positive to an AR-negative disease and efforts to prevent/revert this process and thereby maintain/restore AR-dependence.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) |
UniBE Contributor: |
Rubin, Mark Andrew |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1476-5594 |
Publisher: |
Springer Nature |
Language: |
English |
Submitter: |
Marla Rittiner |
Date Deposited: |
24 Jan 2022 14:10 |
Last Modified: |
05 Dec 2022 16:00 |
Publisher DOI: |
10.1038/s41388-020-01598-0 |
PubMed ID: |
33420371 |
BORIS DOI: |
10.48350/163469 |
URI: |
https://boris.unibe.ch/id/eprint/163469 |
Actions (login required)
 |
Edit item |